# Induction Optimization With Stelara for Crohn's Disease

> **NCT04629196** · PHASE4 · TERMINATED · sponsor: **NYU Langone Health** · enrollment: 12 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Ustekinumab
- **DRUG:** Ustekinumab
- **DRUG:** Ustekinumab

## Key facts

- **NCT ID:** NCT04629196
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-16
- **Primary completion:** 2024-01-17
- **Final completion:** 2024-01-17
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Other effective drugs have been introduced to market since the beginning of the study.
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04629196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04629196, "Induction Optimization With Stelara for Crohn's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04629196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*